The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease

Angiology. 2022 Jan;73(1):5-6. doi: 10.1177/00033197211005597. Epub 2021 Apr 8.

Authors

Konstantinos P Imprialos¹, Konstantinos Stavropoulos¹, Michael Doumas¹, Vasilios G Athyros¹

Affiliation

¹ Second Prop. Department of Internal Medicine, Aristotle University, School of Medicine, Thessaloniki, Greece.

PMID: 33827290
DOI: 10.1177/00033197211005597

No abstract available

Keywords: cardiovascular risk; coronary artery disease; nonalcoholic fatty liver disease; ranolazine; statins.

Publication types

Editorial
Comment

MeSH terms

Coronary Artery Disease* / diagnosis
Coronary Artery Disease* / drug therapy
Humans
Liver Function Tests
Non-alcoholic Fatty Liver Disease* / diagnosis
Non-alcoholic Fatty Liver Disease* / drug therapy
Ranolazine / therapeutic use

Substances

Ranolazine